VRTX vs BMRN Comparison: AI Score, Valuation, Performance and Upside
Compare Vertex Pharmaceuticals and BioMarin by rare disease franchise depth, gene therapy pipeline, pricing power, geographic expansion opportunity, and which rare disease biotech offers better long-term compounding.
Use this Vertex vs BioMarin comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
VRTX and BMRN are closely matched — they split the tracked metrics evenly. VRTX has delivered stronger 1-year price return (+1.08% vs -0.72%), though BMRN has the better forward P/E setup (9.28x vs 22.68x for VRTX). Analyst consensus implies meaningfully more upside for BMRN (+48.19%) than for VRTX (+14.16%).
| Metric | VRTX | BMRN |
|---|---|---|
| AI score | 51.0 | 26.9 |
| AI rank | #447 | #2535 |
| Latest close | $477.36 | $59.33 |
| 1M return | +0.45% | +3.49% |
| 6M return | +1.91% | +3.76% |
| 1Y return | +1.08% | -0.72% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | BMRN |
|---|---|---|
| 1Y ago | $10.16K (+1.6%) started 2025-07-25 | $9.93K (-0.7%) started 2025-07-24 |
| 5Y ago | $24K (+140.0%) started 2021-07-26 | $7.67K (-23.3%) started 2021-07-26 |
| 10Y ago | $49.84K (+398.4%) started 2016-07-25 | $6.39K (-36.1%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | VRTX | BMRN |
|---|---|---|
| Market cap | $123.26B | $11.47B |
| Trailing P/E | 28.82 | 42.68 |
| Forward P/E | 22.68 | 9.28 |
| Price/Sales | 10.42 | 3.54 |
| EV/Revenue | 9.66 | 3.29 |
| Analyst target | $554.43 | $87.92 |
| Target upside | +14.16% | +48.19% |
| Metric | VRTX | BMRN |
|---|---|---|
| Revenue growth | 7.80% | 2.80% |
| Earnings growth | 61.40% | -43.10% |
| EPS growth | +61.40% | -43.10% |
| FCF margin | +22.78% | +14.17% |
| Operating margin | 38.13% | N/A |
| Profit margin | 35.51% | 8.29% |
| ROIC proxy | 24.20% | 4.48% |
| Return on equity | 24.20% | 4.48% |
| Dividend yield | N/A | 0.00% |
| Beta | 0.29 | 0.24 |
| Debt/equity | 10.26 | 23.17 |
| Current ratio | 3.02 | 5.81 |
| Quick ratio | 2.38 | 3.94 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VRTX | BMRN |
|---|---|---|---|
| 1Y | Growth | +1.64% | -0.72% |
| CAGR | +1.65% | -0.72% | |
| Sharpe ratio | 0.10 | 0.01 | |
| Max drawdown | 22.39% | 22.49% | |
| Max daily drop | 20.60% | 4.35% | |
| Max wkly drop | 20.71% | 8.75% | |
| 5Y | Growth | +139.96% | -23.30% |
| CAGR | +19.15% | -5.17% | |
| Sharpe ratio | 0.60 | -0.13 | |
| Max drawdown | 29.07% | 57.64% | |
| Max daily drop | 20.60% | 17.71% | |
| Max wkly drop | 20.71% | 17.74% | |
| 10Y | Growth | +398.44% | -36.06% |
| CAGR | +17.43% | -4.38% | |
| Sharpe ratio | 0.52 | -0.08 | |
| Max drawdown | 41.60% | 62.09% | |
| Max daily drop | 20.70% | 35.28% | |
| Max wkly drop | 22.29% | 38.91% |
| Category | VRTX | BMRN |
|---|---|---|
| Company | VRTX | BMRN |
| Sector | Healthcare | N/A |
| Industry | Biotechnology | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.